We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Coronavirus Detected by Molecular Technique

By LabMedica International staff writers
Posted on 08 Oct 2012
Two polymerase chain reaction (PCR) assays have been developed for the novel human coronavirus that causes a respiratory illness similar to the severe acute respiratory syndrome SARS) virus that spread globally in 2003. More...


Coronaviruses (CoV) are large positive-stranded ribonucleic acid (RNA) viruses causing mainly respiratory and enteric disease in a range of animals and in humans who are known to maintain circulation of four different human coronaviruses (hCoV) at a global population level.

Scientists at the University of Bonn Medical Center (Germany) collaborating with others, developed diagnostic real-time reverse-transcription polymerase chain reaction (RT-PCR) assays suitable for qualitative and quantitative detection of the new agent. They evaluated the technical and analytical performance of these assays.

A provisional genome sequence as well as an isolate of the new virus was obtained. The sequence for the Rotterdam virus isolate, termed hCoV-EMC served as the template for assay design, and the virus was used for initial validation experiments. Respiratory swab, sputum, and endotracheal aspirate material was obtained during 2010–2012 from several hospital wards of the University of Bonn Medical Center.

Upon scanning of a provisional genome assembly, a region upstream of the putative E gene was identified as a particularly suitable target region for a real-time RT-PCR assay. The assay designed for this region is referred to as the upE-assay. A confirmatory test was designed in the open reading frame 1b, termed the ORF1b assay. This target gene did not overlap with those of known pan-CoV assays including the SARS virus that killed hundreds of people in 2003.

To obtain a more clinically relevant figure on assay specificity, the assays were applied on 92 original clinical samples in which other respiratory viruses had already been detected during routine respiratory screening. These samples were prepared using a Viral RNA kit (Qiagen; Hilden, Germany), a formulation widely used to extract RNA in clinical laboratories. Of note, the tested panel included four samples containing hCoV-HKU1, which was not available as cultured virus stock.

In total, none of the 92 original clinical samples, containing a wide range of respiratory viruses, gave any detection signal with either assay while positive controls were readily detected. It was concluded that the assay could be reliably applied to clinical samples. Both assays provided very clear amplification signal on various clinical samples from the patients with the suspected virus. The upE assay appeared more sensitive than the ORF1b assay.

The open availability of proven diagnostic assays early in an epidemic is useful in order to equip and prepare public health laboratories efficiently. The authors will provide in vitro transcribed RNA controls to health professionals, but will not be able to provide intense technical advice. Authors will follow the policy of providing only one control, namely that for the upE assay, in order to minimize opportunities for accidental laboratory contamination. If laboratories find patient samples positive by the upE assay and control, they can conduct confirmatory testing using the ORF1b assay. A positive result in this test would most likely not be due to contamination. The study was published on September 27, 2012, in the journal Eurosurveillance.

Related Links:

University of Bonn Medical Center
Qiagen



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining Management Software
DakoLink
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.